Products for Research Use Only
RegisterLogin

Lirimilast

CAT: 0804-HY-19672-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19672-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD) . Lirimilast has potently anti-inflammatory properties[1][2].
CAS Number
329306-27-6
Product Name Alternative
BAY 19-8004
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lirimilast.html
Concentration
10mM
Purity
98.69
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N)NC1=C(C(C2=CC=C(Cl)C=C2Cl)=O)OC3=CC(OS(=O)(C)=O)=CC=C13
Molecular Formula
C17H12Cl2N2O6S
Molecular Weight
443.26
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Grootendorst DC, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD) . Pulm Pharmacol Ther. 2003;16 (6) :341-7.|[2] Peter Norman. PDE4 inhibitors: sustained patenting activity as leading drugs near the market. Exp. Opin. Ther. Patents (2000) 10 (9) :1415-1427.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE4

Alternative Products

CatalogName
BA8211-1Lirimilast

Popular Products